Literature DB >> 34330897

AKT3-mediated IWS1 phosphorylation promotes the proliferation of EGFR-mutant lung adenocarcinomas through cell cycle-regulated U2AF2 RNA splicing.

Georgios I Laliotis1,2,3,4, Evangelia Chavdoula5,6, Maria D Paraskevopoulou7, Abdul Kaba5,6, Alessandro La Ferlita5,6,8, Satishkumar Singh6,9, Vollter Anastas5,6,10, Keith A Nair5,6, Arturo Orlacchio5,6, Vasiliki Taraslia7,11, Ioannis Vlachos12,13, Marina Capece5,6, Artemis Hatzigeorgiou12, Dario Palmieri5,6, Christos Tsatsanis14,15, Salvatore Alaimo8, Lalit Sehgal6,9, David P Carbone6,16, Vincenzo Coppola5,6, Philip N Tsichlis17,18,19.   

Abstract

AKT-phosphorylated IWS1 regulates alternative RNA splicing via a pathway that is active in lung cancer. RNA-seq studies in lung adenocarcinoma cells lacking phosphorylated IWS1, identified a exon 2-deficient U2AF2 splice variant. Here, we show that exon 2 inclusion in the U2AF2 mRNA is a cell cycle-dependent process that is regulated by LEDGF/SRSF1 splicing complexes, whose assembly is controlled by the IWS1 phosphorylation-dependent deposition of histone H3K36me3 marks in the body of target genes. The exon 2-deficient U2AF2 mRNA encodes a Serine-Arginine-Rich (RS) domain-deficient U2AF65, which is defective in CDCA5 pre-mRNA processing. This results in downregulation of the CDCA5-encoded protein Sororin, a phosphorylation target and regulator of ERK, G2/M arrest and impaired cell proliferation and tumor growth. Analysis of human lung adenocarcinomas, confirmed activation of the pathway in EGFR-mutant tumors and showed that pathway activity correlates with tumor stage, histologic grade, metastasis, relapse after treatment, and poor prognosis.
© 2021. The Author(s).

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34330897      PMCID: PMC8324843          DOI: 10.1038/s41467-021-24795-1

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  75 in total

1.  Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing.

Authors:  Qun Pan; Ofer Shai; Leo J Lee; Brendan J Frey; Benjamin J Blencowe
Journal:  Nat Genet       Date:  2008-11-02       Impact factor: 38.330

2.  IGD: a resource for intronless genes in the human genome.

Authors:  Amel Louhichi; Ahmed Fourati; Ahmed Rebaï
Journal:  Gene       Date:  2011-09-02       Impact factor: 3.688

Review 3.  Hallmarks of alternative splicing in cancer.

Authors:  S Oltean; D O Bates
Journal:  Oncogene       Date:  2013-12-16       Impact factor: 9.867

Review 4.  The roles of RNA processing in translating genotype to phenotype.

Authors:  Kassie S Manning; Thomas A Cooper
Journal:  Nat Rev Mol Cell Biol       Date:  2016-11-16       Impact factor: 94.444

5.  Cotranscriptional coupling of splicing factor recruitment and precursor messenger RNA splicing in mammalian cells.

Authors:  Imke Listerman; Aparna K Sapra; Karla M Neugebauer
Journal:  Nat Struct Mol Biol       Date:  2006-08-20       Impact factor: 15.369

6.  Regulation of alternative splicing by histone modifications.

Authors:  Reini F Luco; Qun Pan; Kaoru Tominaga; Benjamin J Blencowe; Olivia M Pereira-Smith; Tom Misteli
Journal:  Science       Date:  2010-02-04       Impact factor: 47.728

Review 7.  Proteome complexity and the forces that drive proteome imbalance.

Authors:  J Wade Harper; Eric J Bennett
Journal:  Nature       Date:  2016-09-15       Impact factor: 49.962

Review 8.  Alternative splicing and cell survival: from tissue homeostasis to disease.

Authors:  Maria Paola Paronetto; Ilaria Passacantilli; Claudio Sette
Journal:  Cell Death Differ       Date:  2016-09-30       Impact factor: 15.828

9.  An extensive program of periodic alternative splicing linked to cell cycle progression.

Authors:  Daniel Dominguez; Yi-Hsuan Tsai; Robert Weatheritt; Yang Wang; Benjamin J Blencowe; Zefeng Wang
Journal:  Elife       Date:  2016-03-25       Impact factor: 8.140

Review 10.  Alternative pre-mRNA splicing switch controls hESC pluripotency and differentiation.

Authors:  Laura M Agosto; Kristen W Lynch
Journal:  Genes Dev       Date:  2018-09-01       Impact factor: 11.361

View more
  4 in total

Review 1.  Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics.

Authors:  Qiu Peng; Yujuan Zhou; Linda Oyang; Nayiyuan Wu; Yanyan Tang; Min Su; Xia Luo; Ying Wang; Xiaowu Sheng; Jian Ma; Qianjin Liao
Journal:  Mol Ther       Date:  2021-11-15       Impact factor: 11.454

2.  U2 small nuclear RNA auxiliary factor 2, transcriptionally activated by the transcription factor Dp-1/E2F transcription factor 1 complex, enhances the growth and aerobic glycolysis of leiomyosarcoma cells.

Authors:  Yuguo Li; Sihao Chen; Xin Zhang; Naiqiang Zhuo
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

3.  Phosphor-IWS1-dependent U2AF2 splicing regulates trafficking of CAR-E-positive intronless gene mRNAs and sensitivity to viral infection.

Authors:  Georgios I Laliotis; Adam D Kenney; Evangelia Chavdoula; Arturo Orlacchio; Abdul Kaba; Alessandro La Ferlita; Vollter Anastas; Christos Tsatsanis; Joal D Beane; Lalit Sehgal; Vincenzo Coppola; Jacob S Yount; Philip N Tsichlis
Journal:  Commun Biol       Date:  2021-10-11

4.  The Immunohistochemical Expression of the Serine and Arginine-Rich Splicing Factor 1 (SRSF1) Is a Predictive Factor of the Recurrence of Basal Cell Carcinoma: A Preliminary Study on a Series of 52 Cases.

Authors:  Giuseppe Broggi; Davide Barbagallo; Francesco Lacarrubba; Anna Elisa Verzì; Giuseppe Micali; Michele Purrello; Rosario Caltabiano
Journal:  Medicina (Kaunas)       Date:  2022-01-17       Impact factor: 2.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.